Bausch Health unit receives FDA approval for Altreno lotion for acne

Ortho Dermatologics, a division of Bausch Health Companies, announced that the U.S. FDA has approved the New Drug Application for ALTRENO lotion, indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO is the first formulation of tretinoin in a lotion, and has been shown to be effective and generally well-tolerated.ALTRENO is expected to be available during the fourth quarter of 2018. “Today’s FDA approval of ALTRENO builds upon our strong acne portfolio, providing physicians and patients a trusted retinoid in a lotion formulated to enhance the user’s experience with the inclusion of moisturizing attributes of hyaluronic acid, glycerin and collagen,” said Bill Humphries, president, Ortho Dermatologics. “ALTRENO lotion spreads easily and is quickly absorbed into the skin allowing acne patients to easily incorporate this once-daily treatment into their skin care regimen.”

https://bit.ly/2o6ACuY